Dual effects of an anti-CD147 antibody for Esophageal cancer therapy

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Nakajo K, Yoda Y, Hori K, Takashima K, Sinmura K, Oono Y, Ikematsu H, Yano T. Technical feasibility of endoscopic submucosal dissection for local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2018;88(4):637–646. doi:10.1016/j.gie.2018.06.033.
   PubMed Web of Science ®Google Scholar
• Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y, Muto M. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 2015;149(7):1700–1715. doi:10.1053/j.gastro.2015.08.054.
   PubMed Web of Science ®Google Scholar
• Belkhiri A, El-Rifai W. Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget. 2015;6(3):1348–1358. doi:10.18632/oncotarget.2752.
   PubMedGoogle Scholar
• Zhang Y, Ran Y, Yu L, Hu H, Zhou Z, Sun L, Lou J, Yang Z. Monoclonal antibody to human esophageal cancer endothelium inhibits angiogenesis and tumor growth. Anticancer Res. 2006;26(4B):2963–2970.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van CE, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al.; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224–1235. doi:10.1016/S1470-2045(14)70420-6.
   PubMed Web of Science ®Google Scholar
• Lyons TG, Ku GY. Systemic therapy for esophagogastric cancer: targeted therapies. Chin Clin Oncol. 2017 Oct;6(5):48. doi:10.21037/cco.
   PubMed Web of Science ®Google Scholar
• Kanekura T, Miyauchi T, Tashiro M, Muramatsu T. Basigin, a new member of the immunoglobulin superfamily: genes in different mammalian species, glycosylation changes in the molecule from adult organs and possible variation in the N-terminal sequences. Cell Struct Funct. 1991;16:23–30.
   PubMed Web of Science ®Google Scholar
• Feng F, Wang B, Sun X, Zhu Y, Tang H, Nan G, Wang L, Wu B, Huhe M, Liu S, et al. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma. Cancer Biol Ther. 2017;18(1):51–62. doi:10.1080/15384047.2016.1276126.
   PubMed Web of Science ®Google Scholar
• Li H, Jiang C, Wu D, Shi S, Liao M, Wang J, Li Y, Xu Z. The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: A meta-analysis. PLoS One. 2017;12(7):e0180271. doi:10.1371/journal.pone.0180271.
   PubMed Web of Science ®Google Scholar
• Li J, Huang Q, Long X, Zhang J, Huang X, Aa J, Yang H, Chen Z, Xing J. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARalpha pathways. J Hepatol. 2015;63(6):1378–1389. doi:10.1016/j.jhep.2015.07.039.
   PubMed Web of Science ®Google Scholar
• Knutti N, Huber O, Friedrich K. CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways. Mol Cell Biochem. 2019;451(1–2):197–209.
   PubMed Web of Science ®Google Scholar
• Nasry WHS, Wang H, Jones K, Dirksen WP, Rosol TJ, Rodriguez-Lecompte JC, Martin CK. CD147 and cyclooxygenase expression in feline oral squamous cell carcinoma. Vet Sci. 2018;5:3.
   Google Scholar
• Yang H, Chen B. CD147 in ovarian and other cancers. Int J Gynecol Cancer. 2013;23(1):2–8. doi:10.1097/IGC.0b013e3182749139.
   PubMed Web of Science ®Google Scholar
• Xiao W, Zhao S, Shen F, Liang J, Chen J. Overexpression of CD147 is associated with poor prognosis, tumor cell migration and ERK signaling pathway activation in hepatocellular carcinoma. Exp Ther Med. 2017;14(3):2637–2642. doi:10.3892/etm.2017.4818.
   PubMed Web of Science ®Google Scholar
• Zhu S, Li Y, Mi L, Zhang Y, Zhang L, Gong L, Han X, Yao L, Lan M, Chen Z, et al. Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci. 2011;56(12):3569–3576. doi:10.1007/s10620-011-1812-x.
   PubMed Web of Science ®Google Scholar
• Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, et al. A randomized controlled trial of licartin forpreventing hepatoma recurrence after liver transplantation. Hepatology. 2007;45(2):269–276. doi:10.1002/hep.21465.
   PubMed Web of Science ®Google Scholar
• Houghton AN, Scheinberg DA. Monoclonal antibody therapies-a ‘constant’ threat to cancer. Nat Med. 2000;6(4):373–374. doi:10.1038/74621.
   PubMed Web of Science ®Google Scholar
• Yin J, Xu WQ, Ye MX, Zhang Y, Wang HY, Zhang J, Li Y, Wang YS. Up-regulated basigin-2 in microglia induced by hypoxia promotes retinal angiogenesis. J Cell Mol Med. 2017;21(12):3467–3480. doi:10.1111/jcmm.13256.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–446. doi:10.1038/74704.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115–123. doi:10.1053/j.seminhematol.2010.01.011.
   PubMed Web of Science ®Google Scholar
• Barkas T, Al-Khateeb SF. Serum factors influencing antibody-directed cell-mediated cytotoxicity (ADCC) and their effects on the detection of immune complexes by inhibition of ADCC. Immunology. 1979;36(2):299–306.
   PubMed Web of Science ®Google Scholar
• Timonen T. Natural killer cells: endothelial interactions, migration, and target cell recognition. J Leukoc Biol. 1997;62(6):693–701. doi:10.1002/jlb.62.6.693.
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10(2):101–111. doi:10.1038/nrd3365.
   PubMed Web of Science ®Google Scholar
• Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discov Today. 2007;12(21-22:898–910. doi:10.1016/j.drudis.2007.08.009.
   Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004;87(5):614–622. doi:10.1002/bit.20151.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch J. Fcγ receptors as regulators of immune responses. Nature Rev Immunol. 2008;8:34–47. doi:10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Z, Wang N, Chen J, Zhang X, Guo M, John Zhong L, Wang Q. Suppressor of cytokine signalling-2 limits IGF1R-mediated regulation of epithelial-mesenchymal transition in lung adenocarcinoma. Cell Death Dis. 2018 Apr 1;9(4):429. doi:10.1038/s41419-018-1111-y.
   PubMedGoogle Scholar
• Björndahl M, Cao R, Nissen LJ, Clasper S, Johnson LA, Xue Y, Zhou Z, Jackson D, Hansen AJ, Cao Y. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA. 2005;102:15593–15598. doi:10.1073/pnas.0507865102.
   PubMed Web of Science ®Google Scholar